Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-2365-2026

Description/REF: BIOPSY SYSTEM COMPREHENSIVE KIT/ASK-09458-AH, ASK-09458-COC, ASK-09458-EUH, ASK-09458-SD, ASK-09458-VU

Publicado el 24 de junio de 2026 · Inicio del retiro: 21 de abril de 2026

Resumen

FDA registra el retiro Z-2365-2026 de dispositivos médicos de Clase I, publicado el 24 de junio de 2026 e iniciado el 21 de abril de 2026. Empresa responsable: ARROW INTERNATIONAL, LLC; Estado: En curso; Cantidad reportada: 14,840; Lote: REF(Material)/UDI-DI/Lot(Batch): ASK-09458-AH/10801902203172, 10801902193275, 10801902203172/33F24C0359, 33F24C1122, 33F24E0323, 33F24F0780, 33F24K0397, 33F25A0208, 33F25B0518, 33F25D0001, 33F25D0338, 33F25D0465, 33F25E0528, 33F25H0610, 33F25J0353, 33F25K0076, 33F25K0091, 33F25M0173, 33F26A1538, 33F26B0819, 33F24H0227; ASK-09458-COC/10801902193275, 10801902221084, 10801902216394/33F24K0755, 33F25C0380, 33F25D0590, 33F25H0583, 33F25J0354, 33F25K0125, 33F25M0243, 33F25M0393, 33F26A1535, 33F26B0404, 33F24F0732; ASK-09458-EUH/10801902193275, 10801902216394/33F24L0908, 33F25E0715, 33F25F0096, 33F25G0215, 33F25J0144, 33F25M0118, 33F26A1515, 33F26B0862, 33F24H0125; ASK-09458-SD/10801902193275, 10801902215014/33F25D0398, 33F25F0165, 33F25M0692, 33F26C0488; ASK-09458-VU/10801902217261, 10801902193275, 10801902217261, 10801902193275/33F24C0832, 33F24D0624, 33F24F0650, 33F24K0752, 33F24L0916, 33F25D0534, 33F25E0531, 33F25F0141, 33F25H0588, 33F25K0127, 33F25M0177, 33F26B0134, 33F26B0477, 33F26C0487, 33F24H0099. La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.

Estado reportado al momento de publicación: Ongoing — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
ARROW INTERNATIONAL, LLC
Distribuidor
US Nationwide distribution including in the states of VA, NY, UT, SC, LA, MN, PA, AZ, CA, MI, OH, FL, CT, KS, IL, TX, WI, GA, NC, MD, OR, AK, NH, IA, ND, OK, NM, AL, MA, KY, WA, AR, CO, IN, ME, TN, WY, NJ, SD, MS, MO, MT, DE, ID, NE, WV, RI, VT, NV, HI, DC, PR.
Lote
REF(Material)/UDI-DI/Lot(Batch): ASK-09458-AH/10801902203172, 10801902193275, 10801902203172/33F24C0359, 33F24C1122, 33F24E0323, 33F24F0780, 33F24K0397, 33F25A0208, 33F25B0518, 33F25D0001, 33F25D0338, 33F25D0465, 33F25E0528, 33F25H0610, 33F25J0353, 33F25K0076, 33F25K0091, 33F25M0173, 33F26A1538, 33F26B0819, 33F24H0227; ASK-09458-COC/10801902193275, 10801902221084, 10801902216394/33F24K0755, 33F25C0380, 33F25D0590, 33F25H0583, 33F25J0354, 33F25K0125, 33F25M0243, 33F25M0393, 33F26A1535, 33F26B0404, 33F24F0732; ASK-09458-EUH/10801902193275, 10801902216394/33F24L0908, 33F25E0715, 33F25F0096, 33F25G0215, 33F25J0144, 33F25M0118, 33F26A1515, 33F26B0862, 33F24H0125; ASK-09458-SD/10801902193275, 10801902215014/33F25D0398, 33F25F0165, 33F25M0692, 33F26C0488; ASK-09458-VU/10801902217261, 10801902193275, 10801902217261, 10801902193275/33F24C0832, 33F24D0624, 33F24F0650, 33F24K0752, 33F24L0916, 33F25D0534, 33F25E0531, 33F25F0141, 33F25H0588, 33F25K0127, 33F25M0177, 33F26B0134, 33F26B0477, 33F26C0487, 33F24H0099
Clasificación de riesgo
Class I
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Description/REF: BIOPSY SYSTEM COMPREHENSIVE KIT/ASK-09458-AH, ASK-09458-COC, ASK-09458-EUH, ASK-09458-SD, ASK-09458-VU fue retirado del mercado?

Sí. FDA publicó el retiro Z-2365-2026 el 24 de junio de 2026. Peligro reportado: Lidocaine, Bupivacaine, and 0.9% sodium chloride, the subject of a supplier recall, were included into kits and sets. The supplier was found to have quality issues and limited reports of drug ineffectiveness, and if sterility of a water-based injectable product is compromised this could lead to serious or life-threatening injuries.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter